Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
RGEN

RGEN - Repligen Corp Stock Price, Fair Value and News

193.40USD-0.70 (-0.36%)Market Closed
Watchlist

Market Summary

USD193.40-0.70
Market Closed
-0.36%

RGEN Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

RGEN Stock Price

View Fullscreen

RGEN RSI Chart

RGEN Valuation

Market Cap

11.6B

Price/Earnings (Trailing)

279.55

Price/Sales (Trailing)

18.2

EV/EBITDA

81.03

Price/Free Cashflow

149.59

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

10.04%

Return on Equity

2.11%

Return on Assets

1.47%

Free Cashflow Yield

0.67%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

638.8M

Rev. Growth (Yr)

-18.76%

Rev. Growth (Qtr)

10.31%

RGEN Earnings

Earnings (TTM)

41.6M

Earnings Growth (Yr)

-152.31%

Earnings Growth (Qtr)

-240.26%

Breaking Down RGEN Revenue

Last 7 days

1.7%

Last 30 days

20.3%

Last 90 days

38.4%

Trailing 12 Months

13.4%

How does RGEN drawdown profile look like?

RGEN Financial Health

Current Ratio

7.02

RGEN Investor Care

Shares Dilution (1Y)

0.38%

Diluted EPS (TTM)

0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023314.5M422.6M530.7M638.8M
2022734.1M778.8M801.3M206.4M
2021433.0M508.5M592.7M670.5M
2020285.7M302.5M327.1M366.3M
2019209.8M232.8M252.7M270.2M
2018155.5M170.8M183.7M194.0M
2017110.0M113.3M125.2M141.2M
201687.8M95.5M100.4M104.5M
201566.9M72.8M77.5M83.5M
201466.0M64.1M60.4M60.4M
201365.9M67.9M71.6M68.2M
201236.3M44.1M50.6M62.3M
201127.3M27.9M29.3M29.4M
201021.0M22.6M24.1M25.7M

Tracking the Latest Insider Buys and Sells of Repligen Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 14, 2023
hunt anthony
gifted
-
-
-1,000
chief executive officer
Nov 10, 2023
gebski christine
sold
-557,328
147
-3,788
see remarks
Oct 02, 2023
loeillot olivier
acquired
-
-
12,906
president and cco
Sep 25, 2023
garland jason k
acquired
-
-
5,503
cfo
Aug 29, 2023
dawes karen a
acquired
133,943
18.12
7,392
-
Aug 29, 2023
dawes karen a
sold
-145,673
171
-850
-
May 18, 2023
mhatre rohin
acquired
-
-
686
-
May 18, 2023
barthelemy nicolas
acquired
-
-
686
-
May 18, 2023
konstantinov konstantin
acquired
-
-
686
-
May 18, 2023
madaus martin d
acquired
-
-
686
-

1–10 of 50

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
V-Square Quantitative Management LLC
added
76.8
50,683
101,407
0.02%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
2,474,010
21,396,200
0.35%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-10.26
92.00
6,293
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
2.91
589,532
4,196,530
0.02%
Feb 16, 2024
Aspect Partners, LLC
new
-
71,920
71,920
0.05%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
5.48
116,513,000
721,045,000
0.10%
Feb 16, 2024
D L CARLSON INVESTMENT GROUP INC
reduced
-20.76
35,746
1,371,750
0.28%
Feb 15, 2024
Pier Capital, LLC
added
7.84
1,570,400
8,729,830
1.25%
Feb 15, 2024
E. Ohman J:or Asset Management AB
unchanged
-
47,817
413,540
0.01%
Feb 15, 2024
CASTLEARK MANAGEMENT LLC
sold off
-100
-4,032,490
-
-%

1–10 of 39

Are Funds Buying or Selling RGEN?

Are funds buying RGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RGEN
No. of Funds

Unveiling Repligen Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
7.2%
4,012,851
SC 13G/A
Feb 13, 2024
vanguard group inc
9.10%
5,078,261
SC 13G/A
Feb 06, 2024
eddleman roy t
4.85%
2,705,689
SC 13G/A
Jan 23, 2024
blackrock inc.
14.1%
7,859,530
SC 13G/A
Feb 15, 2023
eddleman roy t
4.87%
2,705,689
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
9.1%
5,070,657
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
5,205,155
SC 13G/A
Jan 23, 2023
blackrock inc.
11.0%
6,123,594
SC 13G/A
Sep 08, 2022
blackrock inc.
10.2%
5,686,997
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.5%
3,042,655
SC 13G

Recent SEC filings of Repligen Corp

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 21, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
SC 13G/A
Major Ownership Report
Jan 23, 2024
SC 13G/A
Major Ownership Report
Dec 15, 2023
8-K
Current Report
Dec 15, 2023
4/A
Insider Trading
Dec 07, 2023
8-K
Current Report
Nov 16, 2023
4
Insider Trading

What is the Fair Value of RGEN?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Repligen Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.13
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Repligen Corp News

Latest updates
Yahoo Finance20 hours ago
InvestorsObserver01 Feb 202408:00 am
Yahoo Finance08 Jan 202408:00 am

Repligen Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue10.3%15614115918319220120820618717816314310994.0087.0076.0069.0069.0071.0061.0052.00
Gross Profit-------------60.0054.0051.0044.0039.0038.0040.0034.0028.00
Costs and Expenses14.8%15713614015113814814414614913311510691.0073.0068.0064.0064.0061.0060.0049.0044.00
Operating Expenses-------------91.0073.0068.0064.0064.0061.0060.0049.0044.00
  S&GA Expenses3.7%58.0055.0049.0056.0053.0054.0055.0054.0052.0048.0044.0039.0036.0029.0027.0028.0028.0025.0024.0019.0017.00
  R&D Expenses-2.8%10.0011.0010.0012.0011.0010.0010.0012.009.009.008.008.007.004.004.005.005.005.005.004.003.00
EBITDA Margin-42.0%0.21*0.36*0.52*0.80*1.31*0.31*0.32*0.31*0.30*0.30*0.30*0.28*---------
Interest Expenses323.0%1.000.000.000.000.000.000.000.003.003.003.003.002.003.003.003.003.003.002.002.002.00
Income Taxes357.0%17.00-6.505.007.004.007.0010.0012.006.008.008.004.00-4.923.000.001.001.000.002.002.001.00
Earnings Before Taxes-175.3%-8.7612.0025.0036.0053.0047.0060.0059.0035.0041.0044.0033.0015.0018.0016.0011.004.002.0010.0011.007.00
EBT Margin-57.7%0.10*0.24*0.38*0.62*1.06*0.25*0.25*0.24*0.23*0.23*0.22*0.19*---------
Net Income-240.3%-25.4918.0020.0029.0049.0040.0050.0047.0029.0033.0036.0029.0020.0015.0016.0010.004.002.008.008.006.00
Net Income Margin-70.2%0.07*0.22*0.33*0.53*0.90*0.21*0.20*0.20*0.19*0.20*0.20*0.18*---------
Free Cashflow-41.7%18.0031.0026.003.0041.0030.0020.00-4.0918.0012.0021.002.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets12.3%2,8242,5142,5492,5382,5252,4632,4452,3842,3582,2412,0161,9271,9031,4761,4421,4061,4001,3791,068798775
  Current Assets13.6%1,1119789991,019998953976945932911984926902697687651642622316284276
    Cash Equivalents19.1%751631604517523573597585604621734711717553560539537522218196194
  Inventory-4.3%20221124124523824323921418415613611095.0079.0070.0062.0055.0052.0051.0045.0042.00
  Net PPE2.9%20720220319319117416814812510085.0072.0067.0055.0052.0050.0048.0043.0038.0035.0032.00
  Goodwill13.6%98786987185685685185485986083461861861848213.00468468469470326327
Liabilities62.3%853526578598614627640617608526413371374351342337340334189173159
  Current Liabilities-56.5%15836337440540441142442437534933231331951.0044.0042.0048.0039.00141130130
Shareholder's Equity-0.9%1,9711,9891,9711,9401,9111,8351,8051,7661,7501,7151,6031,5561,5291,1251,1001,0701,0601,045879625616
  Retained Earnings-5.5%43946444642639734930825817.0016513195.0066.0046.0032.0016.006.002.001.00-7.51-0.68
  Additional Paid-In Capital0.1%1,5691,5671,5611,5451,5471,5411,5341,5291,5721,5601,4751,4681,4611,0881,0821,0741,0681,064893646643
Shares Outstanding0.0%56.0056.0056.0056.0056.0056.0055.0055.0055.0055.0055.0055.00---------
Float-------8,912---10,858---5,712---3,600--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-25.9%29,06539,23134,46811,15461,88241,36745,72123,11349,62022,48337,6519,26214,87121,48916,7359,53017,67421,96517,7899,7885,555
  Share Based Compensation1.4%6,4656,3735,4837,2546,2626,1546,9857,9157,0206,8007,1436,5414,5284,2004,1024,1653,3773,2003,0313,2512,520
Cashflow From Investing-1837.3%-169,905-8,77064,833-9,433-121,308-57,494-26,220-28,214-62,276-132,695-17,201-8,997-158,288-33,580-4,480-5,037-7,111-6,892-187,477-3,828-5,457
Cashflow From Financing34563.6%268,127-778-8,825-9,563-2741,251-2,293-12,021231-122345507298,8381,6763,8131,589-180294,875190,12844.001,044

RGEN Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Revenue$ 141,192$ 200,741$ 483,021$ 614,774
Costs and operating expenses:    
Cost of product revenue104,63486,514265,786255,130
Research and development10,57710,22832,43732,823
Selling, general and administrative55,46553,643160,601162,592
Contingent consideration(34,292)(2,309)(31,266)(11,604)
Total costs and operating expenses136,384148,076427,558438,941
Income from operations4,80852,66555,463175,833
Other income (expenses):    
Investment income6,6622,17718,1122,962
Interest expense(269)(329)(813)(892)
Amortization of debt issuance costs(459)(455)(1,373)(1,360)
Other income (expenses)895(6,591)1,500(10,389)
Other income (expenses), net6,829(5,198)17,426(9,679)
Income before income taxes11,63747,46772,889166,154
Income tax (benefit) provision(6,535)7,0625,82428,924
Net income$ 18,172$ 40,405$ 67,065$ 137,230
Earnings per share:    
Basic$ 0.33$ 0.73$ 1.2$ 2.48
Diluted (Note 12)$ 0.32$ 0.71$ 1.18$ 2.39
Weighted average common shares outstanding:    
Basic55,76655,49855,68855,432
Diluted (Note 12)56,94057,30456,93357,598
Net Income (Loss)$ 18,172$ 40,405$ 67,065$ 137,230
Other comprehensive income (loss):    
Foreign currency translation adjustment(6,382)(18,170)(9,177)(38,375)
Comprehensive income11,79022,23557,88898,855
Products    
Revenue:    
Revenue141,156200,708482,910614,668
Royalty and other revenue    
Revenue:    
Revenue$ 36$ 33$ 111$ 106

RGEN Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 630,779$ 523,458
Marketable securities held to maturity0100,299
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively106,158116,247
Inventories, net211,372238,277
Prepaid expenses and other current assets30,14719,837
Total current assets978,456998,118
Property, plant and equipment, net201,618190,673
Intangible assets, net343,729353,676
Goodwill869,252855,513
Deferred tax assets1,546840
Operating lease right of use assets118,084125,023
Other noncurrent assets1,444815
Total noncurrent assets1,535,6731,526,540
Total assets2,514,1292,524,658
Current liabilities:  
Accounts payable18,96127,554
Operating lease liability3,3156,957
Current contingent consideration12,58913,950
Accrued liabilities42,54371,120
Convertible Senior Notes, net285,956284,615
Total current liabilities363,364404,196
Deferred tax liabilities14,03623,000
Noncurrent operating lease liability130,615131,389
Noncurrent contingent consideration13,75951,559
Other noncurrent liabilities3,7983,814
Total noncurrent liabilities162,208209,762
Total liabilities525,572613,958
Commitments and contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding558556
Additional paid-in capital1,567,2331,547,266
Accumulated other comprehensive loss(43,571)(34,394)
Accumulated earnings464,337397,272
Total stockholders' equity1,988,5571,910,700
Total liabilities and stockholders' equity$ 2,514,129$ 2,524,658
RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEwww.repligen.com
 EMPLOYEES2025

Repligen Corp Frequently Asked Questions


What is the ticker symbol for Repligen Corp? What does RGEN stand for in stocks?

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repligen Corp (RGEN)?

As of Thu Feb 22 2024, market cap of Repligen Corp is 10.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers. The fair value of Repligen Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repligen Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repligen Corp a good stock to buy?

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

What is Repligen Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, RGEN's PE ratio (Price to Earnings) is 93.25 and Price to Sales (PS) ratio is 56.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repligen Corp's stock?

In the past 10 years, Repligen Corp has provided 0.294 (multiply by 100 for percentage) rate of return.